Luer lock integrated closure for D2F™ syringes

THE PERFECT  LInC TO YOUR

Drug

More

Fill-Finish

More

End-user

More

Perfect

to Your Drug Products

Ensuring compatibility between drug and closure

The integrated closure of LInC is offered in a variety of carefully selected rubber formulations (FM27, FM30, 7025, 7028), ensuring optimal compatibility with sensitive drugs.

Perfect

to Your Fill-Finish Operations

Maintaining container closure integrity

Inherent to the LInC design is the highly accurate fit of the integrated closure and the rigid cap to luer lock D2F glass syringes, thereby maintaining best container closure integrity.

Fast time to market

D2F-LInC is compatible with existing D2F tub & nest packaging solutions, equivalent to market standards for dimensional, cosmetic, and functional attributes.

Perfect

to Your End-users

Offering an easy opening

A crucial link in the preparation and administration process thanks to an intuitive and easy opening.

Go to article: Home | EDS: Treating a medical zebraGo to article: Scandinavian Health LtdGo to article: EditorialGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Nolato Company Insight Go to article: NolatoGo to article: NewsGo to article: The pharma industry briefingGo to article: Subcuject Company Insight Go to article: SubcujectGo to article: Horizon 2020: a look back at flagship EU pharma projectsGo to article: SanofiGo to article: Sky high: should US drug prices fall in-line with the rest of the world?Go to article: Nipro PharmapackagingGo to article: Q&A: talking drug quality with Valisure, the first analytical pharmacyGo to article: NemeraGo to article: What does ‘ageing’ mean when it comes to drug development? Go to article: Swiss WorldCargoGo to article: Manufacturing medicines in space: how astronauts will make their own drugs Go to article: MimotopesGo to article: Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the deadGo to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Ehlers-Danlos syndrome: The zebra in the roomGo to article: KugelmeiersGo to article: Stop ignoring the two billion: pharma’s role in expanding access to medicineGo to article: SkyepharmaGo to article: IDMP: turning attention to patient benefitsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue